Vera Therapeutics, Inc.
$31.27
-7.9%Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -6.7).
Valuation inputs: P/E -6.7, earnings yield N/A, momentum -7.9%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -49.6%, ROIC -46.3%).
Profitability stack: net margin 0.0%, ROE -49.6%, ROIC -46.3%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +17.7%, momentum -7.9%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Vera Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Vera Therapeutics, Inc. Fair Value Envelope
No Revenue Data
VERA has not reported any revenue values in the available annual periods.
Vera Therapeutics, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
VERA has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
VERA has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
VERA has not reported any net profit margin values in the available annual periods.
Vera Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Vera Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Vera Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that VERA stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 69.40, with estimates ranging from a low of 33.00 to a high of 91.00.
The consensus 1-year price target stands at 69.40, with estimates ranging from a low of 33.00 to a high of 91.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Vera Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $3.77M and sold $4.44M worth of VERA shares, resulting in $673K of net selling activity.
3 Months
0
0.00
28.3K
1.14M
-1.1M
-$1.14M
3-6 Months
5.9K
249.99K
53.5K
2.36M
-2.1M
-$2.11M
6-9 Months
0
0.00
28.9K
943.37K
-943K
-$943K
9-12 Months
166.7K
3.52M
0
0.00
+3.5M
+$3.52M
Top Buyers
Enright Patrick G
Director
$3.77M
Top Sellers
Fordyce Marshall
Director, Officer: President And Ceo
$1.85M
Turner William D.
Officer: Chief Regulatory Officer
$1.45M
Young Joseph R
Officer: Svp, Finance, Chief Acct Offcr
$567K
Grant Sean
Officer: Chief Financial Officer
$208K
Johnson David Lee
Officer: Chief Operating Officer
$108K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $673K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Balanced insider activity: Roughly equal buying and selling suggests normal portfolio management rather than strong directional signals. Look to other metrics for clearer investment insights.
No Dividend Yield Data
VERA has not reported any dividend yield values in the available annual periods.
vera Dividend History
Learning Layer
Related Guides
Build conviction on VERA by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.